| |
| |
|
| Insider
Information: |
Richman Eric I |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
1,259,674 |
|
|
Indirect Shares
|
52,576 |
|
|
| Direct
Value |
$7,050,610 |
|
|
|
Indirect Value
|
$222,156 |
|
|
| Total
Shares |
1,312,250 |
|
|
| Total
Value |
$7,272,767 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Altimmune, Inc |
ALT |
Director |
2016-11-22 |
898,055 |
2016-11-22 |
10,000 |
Premium* |
|
|
ADMA Biologics Inc |
ADMA |
Director |
2020-02-28 |
44,030 |
2015-03-13 |
0 |
Premium* |
|
|
Neubase Therapeutics Ord Shs |
NBSE |
Director |
2022-03-04 |
44,960 |
2022-03-04 |
27,747 |
Premium* |
|
|
Gain Therapeutics, Inc. |
GANX |
Director |
2023-09-20 |
272,629 |
2023-09-20 |
14,829 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GANX |
Gain Therapeutics, Inc. |
Director |
– • – |
2023-09-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
54,900 |
272,629 |
0 |
- |
|
| GANX |
Gain Therapeutics, Inc. |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-05-25 |
4 |
B |
$2.58 |
$6,404 |
D/D |
2,482 |
217,729 |
0.01 |
- |
|
| GANX |
Gain Therapeutics, Inc. |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-05-20 |
4 |
B |
$2.83 |
$26,194 |
D/D |
9,256 |
215,247 |
0.01 |
- |
|
| GANX |
Gain Therapeutics, Inc. |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-05-19 |
4 |
B |
$2.71 |
$10,840 |
D/D |
4,000 |
205,991 |
0.01 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Director |
– • – |
2022-03-04 |
4 |
B |
$1.62 |
$1,620 |
D/D |
1,000 |
44,960 |
2.31 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Director |
– • – |
2022-03-03 |
4 |
B |
$1.72 |
$2,236 |
D/D |
1,300 |
43,960 |
2.31 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Director |
– • – |
2022-03-01 |
4 |
B |
$1.58 |
$2,496 |
D/D |
1,580 |
42,660 |
2.31 |
- |
|
| GANX |
Gain Therapeutics, Inc. |
Chief Executive Officer |
• • – |
2021-08-16 |
4/A |
B |
$7.87 |
$38,716 |
D/D |
4,922 |
216,820 |
2.81 |
- |
|
| GANX |
Gain Therapeutics, Inc. |
Director |
– • – |
2021-08-16 |
4 |
OE |
$7.87 |
$38,716 |
D/D |
4,922 |
216,820 |
0 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Director |
– • – |
2021-04-26 |
4 |
B |
$5.00 |
$25,000 |
D/D |
5,000 |
41,080 |
2.39 |
- |
|
| GANX |
Gain Therapeutics, Inc. |
Chief Executive Officer |
• – – |
2021-03-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
211,898 |
|
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Director |
– • – |
2020-04-30 |
4 |
B |
$6.00 |
$49,998 |
D/D |
8,333 |
36,080 |
2.39 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Director |
– • – |
2020-04-30 |
4 |
B |
$6.00 |
$15,000 |
I/I |
2,500 |
27,747 |
2.1 |
- |
|
| ADMA |
ADMA Biologics Inc |
Director |
– • – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
44,030 |
0 |
- |
|
| NBSE |
Neubase Therapeutics Ord ... |
Director |
– • – |
2019-07-12 |
4 |
A |
$0.00 |
$0 |
I/I |
25,247 |
25,247 |
0 |
- |
|
| ADMA |
ADMA Biologics Inc |
Director |
– • – |
2018-06-08 |
4 |
B |
$4.78 |
$24,999 |
D/D |
5,230 |
36,530 |
2.39 |
- |
|
| ADMA |
ADMA Biologics Inc |
Director |
– • – |
2017-11-09 |
4 |
B |
$2.15 |
$53,750 |
D/D |
25,000 |
31,300 |
2.39 |
- |
|
| ADMA |
ADMA Biologics Inc |
Director |
– • – |
2017-07-13 |
4 |
OE |
$2.68 |
$7,504 |
D/D |
2,800 |
6,300 |
0 |
- |
|
| ALT |
Altimmune, Inc |
Director |
– • – |
2016-11-22 |
4 |
OE |
$1.19 |
$895,213 |
D/D |
483,733 |
898,055 |
0 |
- |
|
| ALT |
Altimmune, Inc |
Director |
– • – |
2016-09-28 |
4 |
OE |
$1.19 |
$343,625 |
D/D |
237,500 |
414,322 |
0 |
- |
|
| ALT |
Altimmune, Inc |
Director |
– • – |
2016-04-13 |
4 |
AS |
$2.20 |
$724,579 |
D/D |
(329,354) |
176,822 |
0 |
- |
|
| ALT |
Altimmune, Inc |
Director |
– • – |
2016-04-13 |
4 |
OE |
$1.16 |
$392,240 |
D/D |
329,354 |
251,822 |
0 |
- |
|
| ALT |
Altimmune, Inc |
Director |
– • – |
2016-04-08 |
4 |
AS |
$2.20 |
$14,080 |
D/D |
(6,400) |
176,822 |
0 |
- |
|
| ALT |
Altimmune, Inc |
Director |
– • – |
2016-04-08 |
4 |
OE |
$1.76 |
$11,264 |
D/D |
6,400 |
183,222 |
0 |
- |
|
| ALT |
Altimmune, Inc |
Director |
– • – |
2016-04-07 |
4 |
AS |
$2.20 |
$11,807 |
D/D |
(5,367) |
176,822 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
